Checking out Cardiome Pharma (CRME)

Technically CRME is setting up for a breakout with Daily and Weekly looking great. Chart below is simple weekly view with no technical studies. Fundamentally, for this small $172 million market cap, here is a note from Brean Capital from August 10 after the last earnings report that gets our attention:

“Product portfolio doubled during the quarter — The company licensed two new products into its portfolio, Esmocard and Trevyent. So far, the company has four products, including three approved IV treatments for serious cardiac conditions (Brinavess, Aggrastat and Esmocard) and one clinical pipeline product in late-stage development (Trevyent). In addition, bringing EU-approved Brinavess into the US market could bring material upside. We expect the company to stay focused on being a global hospital-based specialty pharmaceutical company.”